Stock A017180 MYUNGMOON PHARM CO.,LTD
Add to a list
To use this feature you must be a member
Log inSign up

Financials MYUNGMOON Pharm co.,Ltd

Equities

A017180

KR7017180001

Pharmaceuticals

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
2,090 KRW -0.95% Intraday chart for MYUNGMOON Pharm co.,Ltd +2.20% -8.53%
Mar. 20 MYUNGMOON Pharm co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 Tranche Update on MYUNGMOON Pharm co.,Ltd's Equity Buyback Plan announced on May 25, 2023. CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 126,596 118,913 245,768 159,901 97,023 76,621
Enterprise Value (EV) 1 218,494 228,104 331,474 233,515 170,195 155,439
P/E ratio 128 x -5.83 x -7.7 x -23.3 x 12.3 x -17.1 x
Yield - - - - - -
Capitalization / Revenue 0.86 x 0.8 x 1.92 x 1.16 x 0.64 x 0.45 x
EV / Revenue 1.48 x 1.53 x 2.59 x 1.7 x 1.12 x 0.92 x
EV / EBITDA 31.9 x -21.4 x -13.4 x -139 x 15.9 x 30.3 x
EV / FCF -33.3 x -45.4 x 2,542 x 24.6 x 527 x -23.9 x
FCF Yield -3% -2.2% 0.04% 4.06% 0.19% -4.19%
Price to Book 1.41 x 1.55 x 2.82 x 1.99 x 1.08 x 0.93 x
Nbr of stocks (in thousands) 24,392 24,392 33,806 33,806 33,806 33,532
Reference price 2 5,190 4,875 7,270 4,730 2,870 2,285
Announcement Date 3/14/19 3/17/20 3/19/21 3/15/22 3/22/23 3/20/24
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 147,499 149,346 127,853 137,760 152,135 169,567
EBITDA 1 6,851 -10,635 -24,763 -1,678 10,672 5,132
EBIT 1 4,937 -14,297 -28,964 -5,881 6,434 963.8
Operating Margin 3.35% -9.57% -22.65% -4.27% 4.23% 0.57%
Earnings before Tax (EBT) 1 1,893 -19,184 -27,295 -6,598 2,652 -4,782
Net income 1 988.3 -20,402 -27,639 -6,865 7,868 -4,525
Net margin 0.67% -13.66% -21.62% -4.98% 5.17% -2.67%
EPS 2 40.51 -836.4 -944.1 -203.1 232.7 -134.0
Free Cash Flow 1 -6,565 -5,021 130.4 9,476 322.9 -6,513
FCF margin -4.45% -3.36% 0.1% 6.88% 0.21% -3.84%
FCF Conversion (EBITDA) - - - - 3.03% -
FCF Conversion (Net income) - - - - 4.1% -
Dividend per Share - - - - - -
Announcement Date 3/14/19 3/17/20 3/19/21 3/15/22 3/22/23 3/20/24
1KRW in Million2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 91,897 109,192 85,706 73,614 73,173 78,818
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 13.41 x -10.27 x -3.461 x -43.88 x 6.856 x 15.36 x
Free Cash Flow 1 -6,565 -5,021 130 9,476 323 -6,513
ROE (net income / shareholders' equity) 0.34% -24% -32.5% -7.7% 8.81% -5.3%
ROA (Net income/ Total Assets) 1.29% -3.52% -7.13% -1.58% 1.77% 0.26%
Assets 1 76,574 579,407 387,399 435,454 443,892 -1,754,493
Book Value Per Share 2 3,677 3,137 2,579 2,374 2,648 2,464
Cash Flow per Share 2 25.50 23.50 135.0 202.0 144.0 235.0
Capex 1 10,929 11,970 2,009 375 1,731 2,983
Capex / Sales 7.41% 8.01% 1.57% 0.27% 1.14% 1.76%
Announcement Date 3/14/19 3/17/20 3/19/21 3/15/22 3/22/23 3/20/24
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
MYUNGMOON PHARM CO.,LTD Stock MYUNGMOON Pharm co.,Ltd
-8.53% 51.26M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+29.68% 681B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+19.71% 556B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.35% 361B
MERCK & CO., INC. Stock Merck & Co., Inc.
+17.65% 325B
ABBVIE INC. Stock AbbVie Inc.
+3.77% 285B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.66% 235B
NOVARTIS AG Stock Novartis AG
+4.35% 199B
ROCHE HOLDING AG Stock Roche Holding AG
-11.94% 189B
PFIZER, INC. Stock Pfizer, Inc.
-3.79% 157B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. A017180 Stock
  4. Financials MYUNGMOON Pharm co.,Ltd